SEC Filing Summary: AntriaBio, Inc. (Form 8-K)
Business Context and Reporting Period
This Current Report on Form 8-K was filed by AntriaBio, Inc. on June 5, 2017. The report serves as a Regulation FD disclosure, furnishing a press release dated June 5, 2017 (Exhibit 99.1). The registrant is incorporated in Delaware with principal executive offices in Louisville, CO. Note: The request metadata references "Rezolute, Inc.," but the filing text explicitly identifies the registrant as "AntriaBio, Inc."
Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. This document is a procedural filing to disclose a press release and does not contain a financial statement or quantitative performance data.
Material Changes
The filing does not detail specific material changes to financial position or operations within the text provided. It solely references the issuance of a press release as the event being reported.
Guidance, Outlook, and Risks
Management commentary, guidance, outlook, and specific risk factors are contained within the attached press release (Exhibit 99.1), which is not included in the provided text. The filing explicitly states that the information is "furnished" and not "filed" for purposes of the Securities Exchange Act of 1934, and it shall not be deemed an admission as to the materiality of any information.
Key Facts for Investor Verification
- Verify the content of the press release (Exhibit 99.1) to understand the specific event triggering this disclosure.
- Confirm the correct registrant name is AntriaBio, Inc., not Rezolute, Inc.
- Note that this filing does not constitute a formal filing of the disclosed information under the Exchange Act.
- Review the press release for any forward-looking statements or material updates not present in this summary.